Irbegen Plus (Hydrochlorothiazide, Irbesartan)

• Irbegen Plus, a combination antihypertensive, acts on the renin‑angiotensin system and renal sodium handling to manage hypertension.
• Hypertension: reduces systolic and diastolic blood pressure in adults with primary hypertension.
• Diabetes‑related hypertension: helps control blood pressure and proteinuria in patients with type 2 diabetes.
• Cardiovascular risk reduction: contributes to lower risk of stroke and myocardial infarction by maintaining target blood pressure levels.

• Irbesartan selectively blocks AT1 receptors, preventing angiotensin II‑mediated vasoconstriction and aldosterone release, while hydrochlorothiazide inhibits Na⁺/Cl⁻ reabsorption in the distal convoluted tubule, increasing urinary sodium and water excretion. The combined effect lowers peripheral vascular resistance and plasma volume, resulting in reduced arterial pressure.

Common Side Effects

• Dizziness or light‑headedness, especially after the first dose.
• Headache or mild fatigue.
• Increased urination or nocturia.
• Electrolyte disturbances such as low potassium or sodium.
• Mild gastrointestinal discomfort, including nausea.
• Transient rise in blood glucose levels.

Serious or Rare Side Effects

• Severe dehydration or electrolyte imbalance requiring medical attention.
• Hyperkalemia, particularly when used with potassium‑sparing agents.
• Angioedema or swelling of the face, lips, or throat.
• Acute kidney injury or significant rise in serum creatinine.
• Severe hypotension leading to syncope.
• Pancreatitis or severe allergic reactions.

• Before initiating therapy, clinicians should assess baseline blood pressure, renal function, and electrolyte status.
• Monitor blood pressure regularly: adjust therapy if target levels are not achieved.
• Check electrolytes and renal function: repeat labs within 1–2 weeks after starting.
• Avoid use in severe renal impairment: dose adjustment may be required.
• Use caution in hepatic disease: monitor liver enzymes if clinically indicated.
• Pregnancy and lactation: safety not established; avoid unless clearly needed.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbegen Plus may interact with several medicines that affect blood pressure, electrolytes, or renal function.

Major Interactions (Avoid)

• Aliskiren in patients with diabetes or renal impairment.
• Potassium supplements or potassium‑sparing diuretics (risk of hyperkalemia).
• Lithium (increased lithium levels and toxicity).
• NSAIDs (may reduce antihypertensive effect and impair renal function).
• ACE inhibitors or other ARBs (excessive potassium rise).

Moderate Interactions (Monitor Closely)

• Other antihypertensives (additive blood pressure lowering).
• Diuretics (enhanced electrolyte loss).
• CYP2C9 inhibitors such as fluconazole (may increase irbesartan levels).
• Antidiabetic agents (possible need for dose adjustment).
• Antacids containing aluminum or magnesium (may affect absorption).